These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 22832286)

  • 1. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis.
    Andres M; Sivera F; Pascual E
    J Clin Rheumatol; 2012 Aug; 18(5):234-6. PubMed ID: 22832286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease?
    Pascual E; Andrés M; Sivera F
    Arthritis Res Ther; 2015 Apr; 17(1):89. PubMed ID: 25885915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis.
    Chollet-Janin A; Finckh A; Dudler J; Guerne PA
    Arthritis Rheum; 2007 Feb; 56(2):688-92. PubMed ID: 17265505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
    Narváez J; Díaz-Torné C; Ruiz JM; Hernández MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
    Semin Arthritis Rheum; 2011 Dec; 41(3):401-5. PubMed ID: 21862107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
    Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
    Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial.
    Finckh A; Mc Carthy GM; Madigan A; Van Linthoudt D; Weber M; Neto D; Rappoport G; Blumhardt S; Kyburz D; Guerne PA
    Arthritis Res Ther; 2014 Oct; 16(5):458. PubMed ID: 25315665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis.
    Dervieux T; Furst D; Lein DO; Capps R; Smith K; Walsh M; Kremer J
    Arthritis Rheum; 2004 Sep; 50(9):2766-74. PubMed ID: 15457444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate.
    Lu LJ; Bao CD; Dai M; Teng JL; Fan W; Du F; Yang NP; Zhao YH; Chen ZW; Xu JH; He PG; Wu HX; Tao Y; Zhang MJ; Han XH; Li XF; Gu JR; Li JH; Yu H
    Arthritis Rheum; 2009 Jul; 61(7):979-87. PubMed ID: 19565542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
    Ideguchi H; Ohno S; Ishigatsubo Y
    J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritis.
    Hobl EL; Mader RM; Jilma B; Duhm B; Mustak M; Bröll H; Högger P; Erlacher L
    Clin Ther; 2012 May; 34(5):1195-203. PubMed ID: 22516039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
    Bao C; Chen S; Gu Y; Lao Z; Ni L; Yu Q; Xu J; Li X; Liu J; Sun L; He P; Ma J; Xu S; Ding C
    Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of cyclosporine (Neoral) in rheumatoid arthritis.
    Johns KR; Littlejohn GO
    J Rheumatol; 1999 Oct; 26(10):2110-3. PubMed ID: 10529125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
    Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
    Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.
    Wluka A; Buchbinder R; Mylvaganam A; Hall S; Harkness A; Lewis D; Littlejohn GO; Miller MH; Ryan PF
    J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions.
    Kinder AJ; Hassell AB; Brand J; Brownfield A; Grove M; Shadforth MF
    Rheumatology (Oxford); 2005 Jan; 44(1):61-6. PubMed ID: 15611303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate in the treatment of children with chronic arthritis--long-term observations of efficacy and safety.
    Huang JL
    Br J Clin Pract; 1996 Sep; 50(6):311-4. PubMed ID: 8983319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.